News

• September 21, 2020

  Larimar Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit >

  BALA CYNWYD, Pa. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will virtually

• September 10, 2020

  Larimar Therapeutics to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference >

  BALA CYNWYD, Pa. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will participate in

• August 11, 2020

  Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results >

  Merger between Chondrial Therapeutics and Zafgen completed and company began operating as Larimar Therapeutics Phase 1 clinical trial of CTI-1601 for treatment of Friedreich’s ataxia restarts after delay due to COVID-19 related restrictions $80 million private placement financing completed with

• August 4, 2020

  Larimar Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference >

  BALA CYNWYD, Pa. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will present at the

• July 28, 2020

  Larimar Therapeutics Announces Positive Opinion on Orphan Drug Designation Received from the European Medicines Agency for CTI-1601 for the Treatment of Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , July 28, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP)

• July 20, 2020

  Larimar Therapeutics Announces Dosing of Patients in Third Cohort of Phase 1 SAD Trial of CTI-1601 for Treatment of Friedreich’s Ataxia >

  BALA CYNWYD, Pa. , July 20, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that patients have been dosed in the third cohort of a Phase 1 clinical trial to evaluate

• May 29, 2020

  Larimar Therapeutics to Present at Jefferies Virtual Healthcare Conference >

  BALA CYNWYD, Pa. , May 29, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon , MD, President and Chief Executive Officer, will present at the

• May 29, 2020

  Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics >

  - Shares of combined company to commence trading on Nasdaq Global Market under the symbol “LRMR” on May 29, 2020 - Company signed $80 million in private placement financing with biotechnology focused institutional investors - New Board Chair, Chief Medical Officer and Chief Financial Officer

• December 18, 2019

  Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement >

  Creates clinical-stage company focused on the development of novel protein replacement therapies for rare diseases Chondrial Therapeutics’ lead asset, CTI-1601, currently being evaluated in Phase 1 clinical trial for Friedreich’s ataxia  Companies to host conference call today at 8:30 a.m.

• November 6, 2019

  Zafgen Reports Third Quarter 2019 Financial Results >

  Evaluation of strategic alternatives ongoing BOSTON , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN) today reported its third quarter 2019 financial results. In September 2019 , Zafgen announced plans to explore strategic options to maximize shareholder value and these efforts are

• September 5, 2019

  Zafgen to Explore Strategic Alternatives >

  Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 BOSTON , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology

• August 8, 2019

  Zafgen Reports Second Quarter 2019 Operating and Financial Results >

  Agreement reached with U.S. FDA on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 PATH for PWS study over-enrolled with continued strong support from

• August 6, 2019

  Zafgen to Present at the Wedbush PacGrow Healthcare Conference >

  BOSTON , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

• July 24, 2019

  Zafgen Announces Agreement with U.S. Food and Drug Administration on New Nonclinical Study Design for ZGN-1061 >

  Alignment reached on in vivo animal study design and protocol to translate work from novel in vitro assays and establish relevant safety margins Topline data from the in vivo study expected by the end of 2019 Company has implemented measures to ensure the effective use of capital and extend cash

• June 13, 2019

  Zafgen to Present at the JMP Securities Life Sciences Conference >

  BOSTON , June 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

• June 10, 2019

  Zafgen Presented Full Results of Phase 2 Clinical Trial for ZGN-1061 at the American Diabetes Association's 79th Scientific Sessions >

  Delivered comprehensive oral presentation on both cohorts of the clinical trial, including previously announced results for second cohort evaluating doses up to 1.8 mg Company also presented data demonstrating that treatment with ZGN-1061 improves measures of insulin sensitivity and beta-cell

• May 30, 2019

  Zafgen Announces Regulatory Update on ZGN-1061 >

  Received FDA Type A meeting minutes related to previously announced clinical hold FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively differentiate ZGN-1061 Company is working with FDA to translate in vitro data and confirm

• May 9, 2019

  Zafgen Reports First Quarter 2019 Operating and Financial Results >

  Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061              Company is currently in the formal regulatory process related to the clinical hold for ZGN-1061; Update still anticipated in Q2 2019 PATH for PWS study continues enrollment with strong support

• May 2, 2019

  Zafgen to Announce First Quarter 2019 Financial Results >

  BOSTON , May 02, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will announce

• April 4, 2019

  Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) >

  BOSTON , April 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) (the “Company”) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced that on

• March 13, 2019

  Zafgen to Present at the 31st Annual ROTH Conference >

  BOSTON , March 13, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

• March 11, 2019

  Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates >

  Recently announced positive results for second cohort of Phase 2 clinical trial of ZGN-1061 Updates on progress preparing for FDA Type A meeting for ZGN-1061 Suspends IND filing plans for ZGN-1258 based on nonclinical finding in long-term toxicology studies Expanded executive team with highly

• March 7, 2019

  Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference >

  BOSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield

• March 6, 2019

  Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results >

  BOSTON , March 06, 2019 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a

• March 4, 2019

  Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development >

  BOSTON , March 04, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN) a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced the appointment of

• January 17, 2019

  Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061 >

  Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose relative to placebo Progressive and notable body weight loss occurred at the 1.8 mg dose Results continue

---

View all News >